Clinical Trial Update: Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update exploring whether peripheral blood immunologic biomarkers predict response to adjuvant immune checkpoint inhibition in newly dia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma
• Malignant Glioma

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Glioblastoma, Gliosarcoma | Phase 2 | Status: COMPLETED